Baiju R. Shah, Chairman, Manager
Mr. Shah is Chief Executive Officer of BioMotiv and co-leader of The Harrington Project for Discovery & Development. Prior to BioMotiv, he was President and CEO of BioEnterprise; during Mr. Shah's tenure, the initiative assisted in the creation, recruitment, and acceleration of more than 110 bioscience companies in Cleveland that collectively attracted $1.3 Billion in new funding. He has been named an Ernst & Young Entrepreneur of the Year and has been recognized as one of Cleveland's most influential leaders. He received a J.D. from Harvard Law School and a B.A. from Yale University.
Terry Vance, President, Manager
Terry Vance is the Chief Business Officer of BioMotiv, and serves on the board of Enanta Pharmaceuticals (NASDAQ: ENTA). Before joining BioMotiv, Mr. Vance founded and served as the Managing Member of EGS Healthcare Capital Partners, a venture capital fund that successfully exited four late-stage pharmaceutical companies. Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotech companies.
For fifteen years Mr. Vance was an investment banker at Salomon Brothers and Goldman Sachs, where, as head of Capital Markets for the Northeastern United States, Mr. Vance was an advisor to several pharmaceutical companies, including Merck, Warner-Lambert and American Cyanamid.
Mr. Vance holds an AB degree from Princeton University as well as an MBA degree from Stanford University. He has been a contributing editor to Diabetes Close-Up, an industry publication focused on metabolic disease, especially diabetes and obesity.
Will Charles, Manager
Will Charles has been General Manager of Technology Development at Auckland Uniservices since 2005. During his tenure, UniServices transacted over 165 licensing deals, started 30 companies and raised over $50 million in venture and seed funding for these companies, and has successfully exited a number of them. Will also has extensive commercial experience in businesses in Europe, Asia and New Zealand, having held executive positions at Novartis, GlaxoSmithKline, Roche, Celltech and Wolters Kluwer.
Will has founded and managed a number of funds and private-public partnerships, including the TransTasman Commercialisation Fund, a A$30 million seed fund with four Australian Universities, and the Return on Science, a part of New Zealand’s Ministry of Business, Innovation and Economic Development’s Commercialisation Partner Network. He is also a manager of a number of startups, and has been a guest speaker at international technology transfer conferences such as BioEurope and the Association of Technology Managers in the US (AUTM).